{"ticker": {"uuid": "56535628-7b26-43f9-9d73-60978a9eabdf", "symbol": "GLUE", "name": "Monte Rosa Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "GLUE (NASDAQ: GLUE) holder plans 4,351-share sale after option exercise", "summary": "Jennifer Champoux, a security holder of Monte Rosa Therapeutics (NASDAQ: GLUE), plans to sell 4,351 shares of common stock with an aggregate market value of $101,729.86. This sale, facilitated through UBS Financial Services on NASDAQ, is linked to a cash-funded exercise of stock ", "url": "https://www.stocktitan.net/sec-filings/GLUE/144-monte-rosa-therapeutics-inc-sec-filing-33911f7f8322.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:40:54", "published_display": "15 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading Systems Reacting to (GLUE) Volatility", "summary": "This article analyzes Monte Rosa Therapeutics Inc. (NASDAQ: GLUE), highlighting weak near-term sentiment but strong mid and long-term outlook. It presents three AI-generated trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014along with multi-timeframe signal", "url": "https://news.stocktradersdaily.com/news_release/38/Trading_Systems_Reacting_to_GLUE_Volatility_071526102002_1784125202.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-15T10:20:00", "published_display": "15 Jul 2026 10:20", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX)", "summary": "Two healthcare stocks, Monte Rosa Therapeutics (GLUE) and Neurocrine (NBIX), have received bullish sentiments from analysts. Guggenheim analyst Michael Schmidt reiterated a Buy rating for Monte Rosa Therapeutics with a $35.00 price target, while Wedbush analyst Laura Chico mainta", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NBIX/pressreleases/3270678/analysts-are-bullish-on-these-healthcare-stocks-monte-rosa-therapeutics-glue-neurocrine-nbix/", "source_name": "The Globe and Mail", "published_at": "2026-07-14T11:17:27", "published_display": "14 Jul 2026 11:17", "sentiment": "positive", "sentiment_pct": 85, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 8.7% - Here's What Happened", "summary": "Monte Rosa Therapeutics (NASDAQ:GLUE) experienced an 8.7% stock price drop on Friday, trading as low as $22.90 on unusually low volume. This downturn follows mixed analyst ratings, with several firms cutting targets, and the company missing its last earnings and revenue expectati", "url": "https://www.marketbeat.com/instant-alerts/monte-rosa-therapeutics-nasdaqglue-stock-price-down-87-heres-what-happened-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T16:40:54", "published_display": "10 Jul 2026 16:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (GLUE) Recast As A Growth Name As Valuation Questions Build", "summary": "Monte Rosa Therapeutics (GLUE) has been reclassified into growth indexes such as Russell growth benchmarks, following a significant surge in its share price. While the stock's Price-to-Sales (P/S) ratio of 47.3x suggests it is overvalued compared to industry averages and an estim", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/monte-rosa-therapeutics-glue-recast-as-a-growth-name-as-valu", "source_name": "Simply Wall Street", "published_at": "2026-07-09T19:02:20", "published_display": "09 Jul 2026 19:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "T. Rowe Price reports 8.86M-share stake in Monte Rosa Therapeutics (GLUE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxORkNtc3FnVUpORlBVYU1FN0tFY3NLbURUSHM3czdyS3I5REJaNHRPMlBGaXNZYTBNWjFEVmdORzU1OHJBNGZFWDRlOFpYQVBrRzBiaWhrekxrX2FGS0o1WEhVS1llTWlMZzRJSW5rV1drRnVNc1ZjZUNEdlNURWlmeEl4c2pfeWEzUXNVSFlCQWdneTZBUG11TVpxWjM5bzloX0JrSnA4WFBMN0tnVTRFUVJkd1BPUFBCU0MxQ29aX2pPWWNXN3VzTTh0MA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T15:29:20+00:00", "published_display": "08 Jul 2026 15:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Monte Rosa Therapeutics Inc For: 7 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Monte Rosa Therapeutics Inc. for July 7th. It briefly mentions the document and offers options to view comments, but provides no further details about the filing's content. The rest of the page consists of general fin", "url": "https://ca.investing.com/news/stock-market-news/form-4-monte-rosa-therapeutics-inc-for-7-july-93CH-4723984", "source_name": "Investing.com Canada", "published_at": "2026-07-07T21:11:05", "published_display": "07 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 By Investing.com", "summary": "Sharon Townson, Chief Scientific Officer at Monte Rosa Therapeutics, sold 6,000 shares of common stock for approximately $139,849 after exercising stock options. The sale occurred when the stock was near its 52-week high, and an InvestingPro analysis suggests the shares are overv", "url": "https://ca.investing.com/news/stock-market-news/monte-rosa-therapeutics-cso-sharon-townson-sells-shares-worth-139849-93CH-4723966", "source_name": "Investing.com Canada", "published_at": "2026-07-07T21:11:05", "published_display": "07 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares after option exercise", "summary": "Monte Rosa Therapeutics' Chief Scientific Officer, Sharon Townson, reported an exercise-and-sell transaction involving company stock. She exercised options for 6,000 shares at $6.14 each and subsequently sold all 6,000 shares, including 400 at $24.13 and the remainder at a weight", "url": "https://www.stocktitan.net/sec-filings/GLUE/form-4-monte-rosa-therapeutics-inc-insider-trading-activity-4d2629d76c53.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:11:05", "published_display": "07 Jul 2026 21:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849", "summary": "Monte Rosa Therapeutics CSO Sharon Townson sold 6,000 shares of company stock for approximately $139,849 on July 6, 2026, following the exercise of stock options. The sales were conducted under a Rule 10b5-1 trading plan. This transaction occurred as the stock trades near its 52-", "url": "https://www.investing.com/news/insider-trading-news/monte-rosa-therapeutics-cso-sharon-townson-sells-shares-worth-139849-93CH-4780186", "source_name": "Investing.com", "published_at": "2026-07-07T20:39:55", "published_display": "07 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Monte Rosa Therapeutics Inc For: 6 July By Investing.com", "summary": "This article announces the filing of a Form 4 for Monte Rosa Therapeutics Inc. on July 6th. Form 4 filings typically disclose changes in beneficial ownership of a company's securities by insiders. The brief content provides the headline and mentions Monte Rosa Therapeutics Inc.", "url": "https://ca.investing.com/news/stock-market-news/form-4-monte-rosa-therapeutics-inc-for-6-july-93CH-4721882", "source_name": "Investing.com Canada", "published_at": "2026-07-07T03:09:18", "published_display": "07 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEA adjusts Monte Rosa Therapeutics (GLUE) stake with share distribution and sales", "summary": "New Enterprise Associates (NEA) has updated its ownership in Monte Rosa Therapeutics (GLUE) through a Schedule 13D/A filing. NEA 17, a part of NEA, now holds 6,692,298 shares, representing 7.9% of Monte Rosa's outstanding common stock. This adjustment includes a pro rata distribu", "url": "https://www.stocktitan.net/sec-filings/GLUE/schedule-13d-a-monte-rosa-therapeutics-inc-amended-major-shareholder--125f91368588.html", "source_name": "Stock Titan", "published_at": "2026-07-07T03:09:18", "published_display": "07 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEA funds shift 1,000,000 Monte Rosa shares (NASDAQ: GLUE)", "summary": "NEA-affiliated funds restructured their holdings in Monte Rosa Therapeutics (NASDAQ: GLUE) through a series of internal distributions, not open-market transactions. New Enterprise Associates 17, L.P. distributed 1,000,000 shares pro rata to its partners, and NEA Partners 17 subse", "url": "https://www.stocktitan.net/sec-filings/GLUE/form-4-monte-rosa-therapeutics-inc-insider-trading-activity-0ed32c6b5c38.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:09:18", "published_display": "06 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLUE - Monte Rosa Therapeutics Inc Volatility & Greeks", "summary": "This article provides detailed financial and performance data for Monte Rosa Therapeutics Inc. (GLUE), including its volatility, options Greeks, market capitalization, earnings per share, sales figures, and insider ownership statistics. It also highlights the stock's price perfor", "url": "https://finviz.com/stock?t=GLUE&p=d&b=1&ty=ocv&ov=list_strike&s=30", "source_name": "Finviz", "published_at": "2026-07-06T08:09:18", "published_display": "06 Jul 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of \"Moderate Buy\" by Brokerages", "summary": "Nine brokerages have given Monte Rosa Therapeutics (NASDAQ:GLUE) an average recommendation of \"Moderate Buy,\" with an average 12-month price target of $33.33. Recent analyst target adjustments have been mixed, with some increases and some decreases. Despite recent insider selling", "url": "https://www.marketbeat.com/instant-alerts/monte-rosa-therapeutics-inc-nasdaqglue-given-average-recommendation-of-moderate-buy-by-brokerages-2026-07-05/", "source_name": "MarketBeat", "published_at": "2026-07-05T12:10:42", "published_display": "05 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Monte Rosa Therapeutics, Inc. announced inducement equity awards to three new non-executive employees in accordance with Nasdaq Listing Rule 5635(c)(4). The awards include non-qualified stock options for 18,025 shares and restricted stock units for 3,900 shares, both vesting over", "url": "https://www.sahmcapital.com/news/content/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-04T02:40:09", "published_display": "04 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa lures 3 new hires with stock awards worth 18,025 options", "summary": "Monte Rosa Therapeutics (Nasdaq: GLUE) has granted inducement equity awards to three new non-executive employees under its 2026 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). These awards include options for 18,025 shares at an exercise price of $24.02 and 3,", "url": "https://www.stocktitan.net/news/GLUE/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635-j0bn0p3fkhce.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:12:54", "published_display": "02 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa CMO Filip Janku sells $132k in company stock", "summary": "Monte Rosa Therapeutics CMO Filip Janku sold 5,407 shares of company stock for $132,471 under a pre-arranged trading plan, while simultaneously acquiring the same number of shares by exercising stock options. The sale occurred near the stock's 52-week high after a 425% gain in th", "url": "https://www.investing.com/news/insider-trading-news/monte-rosa-cmo-filip-janku-sells-132k-in-company-stock-93CH-4771670", "source_name": "Investing.com", "published_at": "2026-07-02T13:12:59", "published_display": "02 Jul 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Filip Janku Sells 5,407 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock", "summary": "Filip Janku, an insider at Monte Rosa Therapeutics (NASDAQ:GLUE), sold 5,407 shares of the company's stock for approximately $132,472, reducing his ownership by 8.19%. This sale, along with several others in June, occurred as GLUE shares traded near their 52-week high, despite th", "url": "https://www.marketbeat.com/instant-alerts/filip-janku-sells-5407-shares-of-monte-rosa-therapeutics-nasdaqglue-stock-2026-07-01/", "source_name": "MarketBeat", "published_at": "2026-07-01T21:40:37", "published_display": "01 Jul 2026 21:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (NASDAQ: GLUE) CMO trades 5,407 shares under 10b5-1 plan", "summary": "Monte Rosa Therapeutics' Chief Medical Officer, Filip Janku, exercised stock options for 5,407 shares at $13.41 per share and subsequently sold them at $24.50 per share on June 30, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on March 4, 2026.", "url": "https://www.stocktitan.net/sec-filings/GLUE/form-4-monte-rosa-therapeutics-inc-insider-trading-activity-0914e78b9f30.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:37", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Monte Rosa Therapeutics Inc For: 30 June By Investing.com", "summary": "This article reports on the filing of Form 4 by Monte Rosa Therapeutics Inc. for the period ending June 30. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders when they trade their company's stock. The article mentio", "url": "https://ng.investing.com/news/stock-market-news/form-4-monte-rosa-therapeutics-inc-for-30-june-93CH-2580831", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T13:39:29", "published_display": "01 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics Price Target Raised to $35.00/Share From $30.00 by Guggenheim", "summary": "Guggenheim has increased its price target for Monte Rosa Therapeutics (NASDAQ:GLUE) from $30.00 to $35.00 per share. This adjustment suggests a positive outlook on the company's future performance. However, the report does not provide details on the reasons behind the target rais", "url": "https://www.moomoo.com/news/post/72269340/monte-rosa-therapeutics-price-target-raised-to-35-00-share", "source_name": "Moomoo", "published_at": "2026-07-01T02:40:09", "published_display": "01 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Monte Rosa Therapeutics For: 30 June By Investing.com", "summary": "Investing.com has published a Form 144 filing for Monte Rosa Therapeutics as of June 30th. This brief article primarily lists market data for various indices, commodities, bonds, and shares, along with trending stocks and popular news articles from Investing.com. The information ", "url": "https://ng.investing.com/news/stock-market-news/form-144-monte-rosa-therapeutics-for-30-june-93CH-2581223", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T23:16:00", "published_display": "30 Jun 2026 23:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa (NASDAQ: GLUE) CMO exercises options, sells 6,000 shares", "summary": "Monte Rosa Therapeutics' Chief Medical Officer, Filip Janku, executed an exercise-and-sell transaction, acquiring 6,000 shares at $7.56 per share through stock options and simultaneously selling them at $22.95 per share. These transactions, totaling $137,700 from the sale, were c", "url": "https://www.stocktitan.net/sec-filings/GLUE/form-4-monte-rosa-therapeutics-inc-insider-trading-activity-2bf78f95cfca.html", "source_name": "Stock Titan", "published_at": "2026-06-30T19:39:04", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa (NASDAQ: GLUE) director exercises options, sells 10,000 shares at $23.11", "summary": "Monte Rosa Therapeutics director Anthony M. Manning exercised stock options to acquire 10,000 shares of common stock at $4.16 per share, then immediately sold all 10,000 shares at $23.11 per share in an open-market transaction. Following these transactions, Manning holds 0 direct", "url": "https://www.stocktitan.net/sec-filings/GLUE/form-4-monte-rosa-therapeutics-inc-insider-trading-activity-8e30d98c274b.html", "source_name": "Stock Titan", "published_at": "2026-06-30T19:39:04", "published_display": "30 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLUE (NASDAQ: GLUE) affiliate reports option exercise and 10b5-1 sales in June 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWXlyUkVuNS1VbHBvb0I5U3FSSVNqVjVpU3NsRjkxRUFaMXdKX2VZRl8zZHFnd3pjd184YzBOdmxyWWkzZEc3em8xZmZ0RndscmhsRjJWWk1mUDRjOThxTkxjczlMOXl1cnhjRTQ0WkVmd0x1MVhJQ096bmFrX2l4OFd4YlVOcks2Q1FJRHI3MVlGcEo1bDZKUU5oQll4V1Q1RjNCaVJrQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (GLUE) Joins Russell Growth Indexes, Is The Upside Already Priced In?", "summary": "Monte Rosa Therapeutics (GLUE) has been added to several Russell growth indexes following strong recent stock performance, including a 429.93% return over one year. The company is currently unprofitable and trades at a high price-to-sales (P/S) ratio of 47x, significantly above i", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/monte-rosa-therapeutics-glue-joins-russell-growth-indexes-is", "source_name": "Simply Wall Street", "published_at": "2026-06-30T07:10:41", "published_display": "30 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLUE (NASDAQ: GLUE) option exercise; insider 10b5-1 sales total 41,845 shares", "summary": "Monte Rosa Therapeutics (NASDAQ: GLUE) insider filed a Form 144, disclosing the exercise of 6,000 stock options and subsequent 10b5-1 sales totaling 41,845 shares. These sales, executed on June 23 and June 24, 2026, generated total proceeds of $882,203.50. This routine transactio", "url": "https://www.stocktitan.net/sec-filings/GLUE/144-monte-rosa-therapeutics-inc-sec-filing-660042515407.html", "source_name": "Stock Titan", "published_at": "2026-06-30T00:10:28", "published_display": "30 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?", "summary": "", "url": "https://finance.yahoo.com/m/d3d11f0e-831f-339b-b841-ead0aad11b1f/after-a-400%25-surge%2C-should.html", "source_name": "Motley Fool", "published_at": "2026-06-29T22:50:47+00:00", "published_display": "29 Jun 2026 22:50", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Monte Rosa Therapeutics' (GLUE) Shift Into Russell Growth Indices Recast Its Biotech Risk Profile?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-29T01:21:15+00:00", "published_display": "29 Jun 2026 01:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa (GLUE) CMO sells 41,845 shares after exercising options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQLXRyXzI0aWtFMEZSU0VldG9nOHQ0R2VRd2c2dUQ2Wi02ZjRZTnNDdzdwakdDOF84OHFvSXhmUnBqVXZjajNaaFhXcG9OZFhjNkpnc1JKbU4tUVh3bnR6czRvR000TmVvdEI0SUMyWlJTVUFVYlVtckxLaGUzV3NFZEpydGtGZC0teTRlRFJXcVFTRXlsR2RMRGtxS0duZ21Yamx3QWV3UXVuX2MwT1pWTEtvaWt5SC1wajRJWUFB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 7.8% - Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbmFrLTBYV1NCR3NTV0xqdm5qcC1rMEtCbUsxVElObjFsZ2E3MFJlellVQ0Q4ZlJrZ3VQY01WeUlBMF9wOHJLQlg4c09vX0ZBUzROVEp0NmZZMkFDNzJ4c0lKQU82N3l4R2VwSnJFem1WNXZrWjNlQjVPQUsxN1QwR1NhYnd0ekk0NDlwWUNGM19yT2phLU1CUVJRZ3doM09wc3Y0ZG9fOU56TGp5VWhKWGthajNwc00?oc=5", "source_name": "MarketBeat", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLUE (NASDAQ: GLUE) insider files Form 144 to sell 11,845 shares on 06/23/2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPS1RuSlZnMmpZa21XcC1OdTRmN3hvY3Q4c2tMY0s0TmdlazFTVjRwdTN3NTRqZ0tYM0lwclNiUGRuSnJYbmZvQnA4RDMwdndUMW5jaFNydTJqbl94TENwSkRvOHdMUDlpT3JmZmxDa0tHOFd3NU5jb2pWN05sdGlCUzJnQ0dLZ3drYlh2dlZyZXNXWHdpa0pGWmlRejlKaTh1X0dBYXNwdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa (NASDAQ: GLUE) CSO sells 3,000 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOVWh4cTFpenFWMHRhYWhObE5Hei1xX3BadnhpNUVSTDk1RVlTeUk2RmlWb1pOUU9vdktzbXh4MUxjTU5iS3R3WjJyUl9HSU4zTWtsNUtJSkNvSkVIRXNGWm5jWE5aa1hKSm93Ykg4MHhFNGUwRGE1RV9OcDE1LUFCcUpyZG5GN1Zlb3J4Ti1nQ0kzbktvSUFNNFdNZnZ1MXNEcnlnY3hBVHQ3aHJFcGRPUUs1czZXQVhDb0dHLVhB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Monte Rosa (GLUE) awarded 25,800 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOQWVDNnhidXdaWW5xZDN0TEgxM0xYc2FCY2VJSGRqMnpaUEZ1cjVkdlBhUDBWVDd2VkFScTNYTUZJY1NlZnYyNFYtaEhIczJVY0xyVUZqVGxiOEZKUzlnSnd6alhFWmJCWXVZU3J0SzM1Y05uYzNUV0dOMi1ES3dReWZRYnpBZXJXOUNFUERqZ2Y3ZlFrMDFEVEpkYzR5dzZRQ18ta1JuSVVmY08tMVB6Ul9kZTVPSDBvQUk0YW9B?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monte-rosa-therapeutics-glue-best-180019178.html", "source_name": "Insider Monkey", "published_at": "2026-06-03T18:00:19+00:00", "published_display": "03 Jun 2026 18:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monte-rosa-therapeutics-participate-upcoming-110000322.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T11:00:00+00:00", "published_display": "20 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/monte-rosa-trial-progress-valuation-002431921.html", "source_name": "Simply Wall St.", "published_at": "2026-05-10T00:24:31+00:00", "published_display": "10 May 2026 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monte-rosa-therapeutics-glue-reports-151505773.html", "source_name": "Zacks", "published_at": "2026-05-07T15:15:05+00:00", "published_display": "07 May 2026 15:15", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monte-rosa-therapeutics-q1-earnings-131804201.html", "source_name": "Associated Press", "published_at": "2026-05-07T13:18:04+00:00", "published_display": "07 May 2026 13:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monte-rosa-therapeutics-announces-first-110000914.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T11:00:00+00:00", "published_display": "07 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise", "summary": "", "url": "https://finance.yahoo.com/m/23019c27-1112-378b-859e-30d2884f46b1/monte-rosa-ceo-sells-%24141k-in.html", "source_name": "Motley Fool", "published_at": "2026-04-21T17:53:49+00:00", "published_display": "21 Apr 2026 17:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What You Need To Know About The Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Analyst Downgrade Today", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Market Doesn't Like What It Sees From Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Revenues Yet As Shares Tumble 26%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-14T08:00:00+00:00", "published_display": "14 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxNNERPc0lNSThISlE4cno3c2pOS1M0bGV1VTZnTHI5NHJSVDdZdS1tdk4tZUlyM29xZUtjbmxodGQteVUxaVd2bDZyTzVUR0VKcGRkVGUwVkFoWm9CWlZNR2k4RUlXOHhSSnJMQnNnWGdfbjlHT0pYdTdpUXJ2eEdEdENUMWNMejlTbjBiTXN4SC1wVFlZNnZ4MnJOQ1RmWFFVT2szd1piTXlOTXRRY2dxM0V6TmF0M3FGOC1HTHYwbXBmQVhORktpcUtlRkY0V1p0c2VqYnl0ODl0dDF1ZmVhdTNSVmZSWjNjY0FMTFVEMTFKTldSeEMxZWNJRjhjUkU?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics And The Promise Of Molecular Glue Degraders", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOeHQwWjJKY1I2YWhrY0gwa2kxb01GU1Jvak16ZWV6b0p2ZGp1VFNYTFpfUG5DaTlsU1E1bmJITldzNHBVN1R4d2VnRllNQ0FWWGhHTXZ2MFNoUWRvY29kMzhlSDRwcWNaakhEbTlwMGNlZFhsSV9aYU8yeUxfSXVJV1Z6d3d6bjZuZUxPX1VYVExyc3pzdmYwMmRCTWtETWJsX1l1Rlg3Vy1fcXM4?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-09-16T07:00:00+00:00", "published_display": "16 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "GLUE (NASDAQ: GLUE) holder plans 4,351-share sale after option exercise", "summary": "Jennifer Champoux, a security holder of Monte Rosa Therapeutics (NASDAQ: GLUE), plans to sell 4,351 shares of common stock with an aggregate market value of $101,729.86. This sale, facilitated through UBS Financial Services on NASDAQ, is linked to a cash-funded exercise of stock ", "url": "https://www.stocktitan.net/sec-filings/GLUE/144-monte-rosa-therapeutics-inc-sec-filing-33911f7f8322.html", "source_name": "Stock Titan", "published_at": "2026-07-15T20:40:54", "published_display": "15 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trading Systems Reacting to (GLUE) Volatility", "summary": "This article analyzes Monte Rosa Therapeutics Inc. (NASDAQ: GLUE), highlighting weak near-term sentiment but strong mid and long-term outlook. It presents three AI-generated trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging\u2014along with multi-timeframe signal", "url": "https://news.stocktradersdaily.com/news_release/38/Trading_Systems_Reacting_to_GLUE_Volatility_071526102002_1784125202.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-15T10:20:00", "published_display": "15 Jul 2026 10:20", "sentiment": "positive", "sentiment_pct": 74, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX)", "summary": "Two healthcare stocks, Monte Rosa Therapeutics (GLUE) and Neurocrine (NBIX), have received bullish sentiments from analysts. Guggenheim analyst Michael Schmidt reiterated a Buy rating for Monte Rosa Therapeutics with a $35.00 price target, while Wedbush analyst Laura Chico mainta", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NBIX/pressreleases/3270678/analysts-are-bullish-on-these-healthcare-stocks-monte-rosa-therapeutics-glue-neurocrine-nbix/", "source_name": "The Globe and Mail", "published_at": "2026-07-14T11:17:27", "published_display": "14 Jul 2026 11:17", "sentiment": "positive", "sentiment_pct": 85, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 8.7% - Here's What Happened", "summary": "Monte Rosa Therapeutics (NASDAQ:GLUE) experienced an 8.7% stock price drop on Friday, trading as low as $22.90 on unusually low volume. This downturn follows mixed analyst ratings, with several firms cutting targets, and the company missing its last earnings and revenue expectati", "url": "https://www.marketbeat.com/instant-alerts/monte-rosa-therapeutics-nasdaqglue-stock-price-down-87-heres-what-happened-2026-07-10/", "source_name": "MarketBeat", "published_at": "2026-07-10T16:40:54", "published_display": "10 Jul 2026 16:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (GLUE) Recast As A Growth Name As Valuation Questions Build", "summary": "Monte Rosa Therapeutics (GLUE) has been reclassified into growth indexes such as Russell growth benchmarks, following a significant surge in its share price. While the stock's Price-to-Sales (P/S) ratio of 47.3x suggests it is overvalued compared to industry averages and an estim", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/monte-rosa-therapeutics-glue-recast-as-a-growth-name-as-valu", "source_name": "Simply Wall Street", "published_at": "2026-07-09T19:02:20", "published_display": "09 Jul 2026 19:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "T. Rowe Price reports 8.86M-share stake in Monte Rosa Therapeutics (GLUE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxORkNtc3FnVUpORlBVYU1FN0tFY3NLbURUSHM3czdyS3I5REJaNHRPMlBGaXNZYTBNWjFEVmdORzU1OHJBNGZFWDRlOFpYQVBrRzBiaWhrekxrX2FGS0o1WEhVS1llTWlMZzRJSW5rV1drRnVNc1ZjZUNEdlNURWlmeEl4c2pfeWEzUXNVSFlCQWdneTZBUG11TVpxWjM5bzloX0JrSnA4WFBMN0tnVTRFUVJkd1BPUFBCU0MxQ29aX2pPWWNXN3VzTTh0MA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-08T15:29:20+00:00", "published_display": "08 Jul 2026 15:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Monte Rosa Therapeutics Inc For: 7 July By Investing.com", "summary": "This article from Investing.com reports on a Form 4 filing for Monte Rosa Therapeutics Inc. for July 7th. It briefly mentions the document and offers options to view comments, but provides no further details about the filing's content. The rest of the page consists of general fin", "url": "https://ca.investing.com/news/stock-market-news/form-4-monte-rosa-therapeutics-inc-for-7-july-93CH-4723984", "source_name": "Investing.com Canada", "published_at": "2026-07-07T21:11:05", "published_display": "07 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 By Investing.com", "summary": "Sharon Townson, Chief Scientific Officer at Monte Rosa Therapeutics, sold 6,000 shares of common stock for approximately $139,849 after exercising stock options. The sale occurred when the stock was near its 52-week high, and an InvestingPro analysis suggests the shares are overv", "url": "https://ca.investing.com/news/stock-market-news/monte-rosa-therapeutics-cso-sharon-townson-sells-shares-worth-139849-93CH-4723966", "source_name": "Investing.com Canada", "published_at": "2026-07-07T21:11:05", "published_display": "07 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares after option exercise", "summary": "Monte Rosa Therapeutics' Chief Scientific Officer, Sharon Townson, reported an exercise-and-sell transaction involving company stock. She exercised options for 6,000 shares at $6.14 each and subsequently sold all 6,000 shares, including 400 at $24.13 and the remainder at a weight", "url": "https://www.stocktitan.net/sec-filings/GLUE/form-4-monte-rosa-therapeutics-inc-insider-trading-activity-4d2629d76c53.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:11:05", "published_display": "07 Jul 2026 21:11", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849", "summary": "Monte Rosa Therapeutics CSO Sharon Townson sold 6,000 shares of company stock for approximately $139,849 on July 6, 2026, following the exercise of stock options. The sales were conducted under a Rule 10b5-1 trading plan. This transaction occurred as the stock trades near its 52-", "url": "https://www.investing.com/news/insider-trading-news/monte-rosa-therapeutics-cso-sharon-townson-sells-shares-worth-139849-93CH-4780186", "source_name": "Investing.com", "published_at": "2026-07-07T20:39:55", "published_display": "07 Jul 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Monte Rosa Therapeutics Inc For: 6 July By Investing.com", "summary": "This article announces the filing of a Form 4 for Monte Rosa Therapeutics Inc. on July 6th. Form 4 filings typically disclose changes in beneficial ownership of a company's securities by insiders. The brief content provides the headline and mentions Monte Rosa Therapeutics Inc.", "url": "https://ca.investing.com/news/stock-market-news/form-4-monte-rosa-therapeutics-inc-for-6-july-93CH-4721882", "source_name": "Investing.com Canada", "published_at": "2026-07-07T03:09:18", "published_display": "07 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEA adjusts Monte Rosa Therapeutics (GLUE) stake with share distribution and sales", "summary": "New Enterprise Associates (NEA) has updated its ownership in Monte Rosa Therapeutics (GLUE) through a Schedule 13D/A filing. NEA 17, a part of NEA, now holds 6,692,298 shares, representing 7.9% of Monte Rosa's outstanding common stock. This adjustment includes a pro rata distribu", "url": "https://www.stocktitan.net/sec-filings/GLUE/schedule-13d-a-monte-rosa-therapeutics-inc-amended-major-shareholder--125f91368588.html", "source_name": "Stock Titan", "published_at": "2026-07-07T03:09:18", "published_display": "07 Jul 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEA funds shift 1,000,000 Monte Rosa shares (NASDAQ: GLUE)", "summary": "NEA-affiliated funds restructured their holdings in Monte Rosa Therapeutics (NASDAQ: GLUE) through a series of internal distributions, not open-market transactions. New Enterprise Associates 17, L.P. distributed 1,000,000 shares pro rata to its partners, and NEA Partners 17 subse", "url": "https://www.stocktitan.net/sec-filings/GLUE/form-4-monte-rosa-therapeutics-inc-insider-trading-activity-0ed32c6b5c38.html", "source_name": "Stock Titan", "published_at": "2026-07-06T22:09:18", "published_display": "06 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLUE - Monte Rosa Therapeutics Inc Volatility & Greeks", "summary": "This article provides detailed financial and performance data for Monte Rosa Therapeutics Inc. (GLUE), including its volatility, options Greeks, market capitalization, earnings per share, sales figures, and insider ownership statistics. It also highlights the stock's price perfor", "url": "https://finviz.com/stock?t=GLUE&p=d&b=1&ty=ocv&ov=list_strike&s=30", "source_name": "Finviz", "published_at": "2026-07-06T08:09:18", "published_display": "06 Jul 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of \"Moderate Buy\" by Brokerages", "summary": "Nine brokerages have given Monte Rosa Therapeutics (NASDAQ:GLUE) an average recommendation of \"Moderate Buy,\" with an average 12-month price target of $33.33. Recent analyst target adjustments have been mixed, with some increases and some decreases. Despite recent insider selling", "url": "https://www.marketbeat.com/instant-alerts/monte-rosa-therapeutics-inc-nasdaqglue-given-average-recommendation-of-moderate-buy-by-brokerages-2026-07-05/", "source_name": "MarketBeat", "published_at": "2026-07-05T12:10:42", "published_display": "05 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "Monte Rosa Therapeutics, Inc. announced inducement equity awards to three new non-executive employees in accordance with Nasdaq Listing Rule 5635(c)(4). The awards include non-qualified stock options for 18,025 shares and restricted stock units for 3,900 shares, both vesting over", "url": "https://www.sahmcapital.com/news/content/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2026-07-02", "source_name": "Sahm", "published_at": "2026-07-04T02:40:09", "published_display": "04 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa lures 3 new hires with stock awards worth 18,025 options", "summary": "Monte Rosa Therapeutics (Nasdaq: GLUE) has granted inducement equity awards to three new non-executive employees under its 2026 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). These awards include options for 18,025 shares at an exercise price of $24.02 and 3,", "url": "https://www.stocktitan.net/news/GLUE/monte-rosa-reports-inducement-grants-under-nasdaq-listing-rule-5635-j0bn0p3fkhce.html", "source_name": "Stock Titan", "published_at": "2026-07-02T20:12:54", "published_display": "02 Jul 2026 20:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa CMO Filip Janku sells $132k in company stock", "summary": "Monte Rosa Therapeutics CMO Filip Janku sold 5,407 shares of company stock for $132,471 under a pre-arranged trading plan, while simultaneously acquiring the same number of shares by exercising stock options. The sale occurred near the stock's 52-week high after a 425% gain in th", "url": "https://www.investing.com/news/insider-trading-news/monte-rosa-cmo-filip-janku-sells-132k-in-company-stock-93CH-4771670", "source_name": "Investing.com", "published_at": "2026-07-02T13:12:59", "published_display": "02 Jul 2026 13:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Filip Janku Sells 5,407 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock", "summary": "Filip Janku, an insider at Monte Rosa Therapeutics (NASDAQ:GLUE), sold 5,407 shares of the company's stock for approximately $132,472, reducing his ownership by 8.19%. This sale, along with several others in June, occurred as GLUE shares traded near their 52-week high, despite th", "url": "https://www.marketbeat.com/instant-alerts/filip-janku-sells-5407-shares-of-monte-rosa-therapeutics-nasdaqglue-stock-2026-07-01/", "source_name": "MarketBeat", "published_at": "2026-07-01T21:40:37", "published_display": "01 Jul 2026 21:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (NASDAQ: GLUE) CMO trades 5,407 shares under 10b5-1 plan", "summary": "Monte Rosa Therapeutics' Chief Medical Officer, Filip Janku, exercised stock options for 5,407 shares at $13.41 per share and subsequently sold them at $24.50 per share on June 30, 2026. This transaction was conducted under a Rule 10b5-1 trading plan established on March 4, 2026.", "url": "https://www.stocktitan.net/sec-filings/GLUE/form-4-monte-rosa-therapeutics-inc-insider-trading-activity-0914e78b9f30.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:40:37", "published_display": "01 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Monte Rosa Therapeutics Inc For: 30 June By Investing.com", "summary": "This article reports on the filing of Form 4 by Monte Rosa Therapeutics Inc. for the period ending June 30. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders when they trade their company's stock. The article mentio", "url": "https://ng.investing.com/news/stock-market-news/form-4-monte-rosa-therapeutics-inc-for-30-june-93CH-2580831", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T13:39:29", "published_display": "01 Jul 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics Price Target Raised to $35.00/Share From $30.00 by Guggenheim", "summary": "Guggenheim has increased its price target for Monte Rosa Therapeutics (NASDAQ:GLUE) from $30.00 to $35.00 per share. This adjustment suggests a positive outlook on the company's future performance. However, the report does not provide details on the reasons behind the target rais", "url": "https://www.moomoo.com/news/post/72269340/monte-rosa-therapeutics-price-target-raised-to-35-00-share", "source_name": "Moomoo", "published_at": "2026-07-01T02:40:09", "published_display": "01 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Monte Rosa Therapeutics For: 30 June By Investing.com", "summary": "Investing.com has published a Form 144 filing for Monte Rosa Therapeutics as of June 30th. This brief article primarily lists market data for various indices, commodities, bonds, and shares, along with trending stocks and popular news articles from Investing.com. The information ", "url": "https://ng.investing.com/news/stock-market-news/form-144-monte-rosa-therapeutics-for-30-june-93CH-2581223", "source_name": "Investing.com Nigeria", "published_at": "2026-06-30T23:16:00", "published_display": "30 Jun 2026 23:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa (NASDAQ: GLUE) CMO exercises options, sells 6,000 shares", "summary": "Monte Rosa Therapeutics' Chief Medical Officer, Filip Janku, executed an exercise-and-sell transaction, acquiring 6,000 shares at $7.56 per share through stock options and simultaneously selling them at $22.95 per share. These transactions, totaling $137,700 from the sale, were c", "url": "https://www.stocktitan.net/sec-filings/GLUE/form-4-monte-rosa-therapeutics-inc-insider-trading-activity-2bf78f95cfca.html", "source_name": "Stock Titan", "published_at": "2026-06-30T19:39:04", "published_display": "30 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa (NASDAQ: GLUE) director exercises options, sells 10,000 shares at $23.11", "summary": "Monte Rosa Therapeutics director Anthony M. Manning exercised stock options to acquire 10,000 shares of common stock at $4.16 per share, then immediately sold all 10,000 shares at $23.11 per share in an open-market transaction. Following these transactions, Manning holds 0 direct", "url": "https://www.stocktitan.net/sec-filings/GLUE/form-4-monte-rosa-therapeutics-inc-insider-trading-activity-8e30d98c274b.html", "source_name": "Stock Titan", "published_at": "2026-06-30T19:39:04", "published_display": "30 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLUE (NASDAQ: GLUE) affiliate reports option exercise and 10b5-1 sales in June 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPWXlyUkVuNS1VbHBvb0I5U3FSSVNqVjVpU3NsRjkxRUFaMXdKX2VZRl8zZHFnd3pjd184YzBOdmxyWWkzZEc3em8xZmZ0RndscmhsRjJWWk1mUDRjOThxTkxjczlMOXl1cnhjRTQ0WkVmd0x1MVhJQ096bmFrX2l4OFd4YlVOcks2Q1FJRHI3MVlGcEo1bDZKUU5oQll4V1Q1RjNCaVJrQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (GLUE) Joins Russell Growth Indexes, Is The Upside Already Priced In?", "summary": "Monte Rosa Therapeutics (GLUE) has been added to several Russell growth indexes following strong recent stock performance, including a 429.93% return over one year. The company is currently unprofitable and trades at a high price-to-sales (P/S) ratio of 47x, significantly above i", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glue/monte-rosa-therapeutics/news/monte-rosa-therapeutics-glue-joins-russell-growth-indexes-is", "source_name": "Simply Wall Street", "published_at": "2026-06-30T07:10:41", "published_display": "30 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLUE (NASDAQ: GLUE) option exercise; insider 10b5-1 sales total 41,845 shares", "summary": "Monte Rosa Therapeutics (NASDAQ: GLUE) insider filed a Form 144, disclosing the exercise of 6,000 stock options and subsequent 10b5-1 sales totaling 41,845 shares. These sales, executed on June 23 and June 24, 2026, generated total proceeds of $882,203.50. This routine transactio", "url": "https://www.stocktitan.net/sec-filings/GLUE/144-monte-rosa-therapeutics-inc-sec-filing-660042515407.html", "source_name": "Stock Titan", "published_at": "2026-06-30T00:10:28", "published_display": "30 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale?", "summary": "", "url": "https://finance.yahoo.com/m/d3d11f0e-831f-339b-b841-ead0aad11b1f/after-a-400%25-surge%2C-should.html", "source_name": "Motley Fool", "published_at": "2026-06-29T22:50:47+00:00", "published_display": "29 Jun 2026 22:50", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Monte Rosa Therapeutics' (GLUE) Shift Into Russell Growth Indices Recast Its Biotech Risk Profile?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-29T01:21:15+00:00", "published_display": "29 Jun 2026 01:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa (GLUE) CMO sells 41,845 shares after exercising options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQLXRyXzI0aWtFMEZSU0VldG9nOHQ0R2VRd2c2dUQ2Wi02ZjRZTnNDdzdwakdDOF84OHFvSXhmUnBqVXZjajNaaFhXcG9OZFhjNkpnc1JKbU4tUVh3bnR6czRvR000TmVvdEI0SUMyWlJTVUFVYlVtckxLaGUzV3NFZEpydGtGZC0teTRlRFJXcVFTRXlsR2RMRGtxS0duZ21Yamx3QWV3UXVuX2MwT1pWTEtvaWt5SC1wajRJWUFB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Up 7.8% - Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxQbmFrLTBYV1NCR3NTV0xqdm5qcC1rMEtCbUsxVElObjFsZ2E3MFJlellVQ0Q4ZlJrZ3VQY01WeUlBMF9wOHJLQlg4c09vX0ZBUzROVEp0NmZZMkFDNzJ4c0lKQU82N3l4R2VwSnJFem1WNXZrWjNlQjVPQUsxN1QwR1NhYnd0ekk0NDlwWUNGM19yT2phLU1CUVJRZ3doM09wc3Y0ZG9fOU56TGp5VWhKWGthajNwc00?oc=5", "source_name": "MarketBeat", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GLUE (NASDAQ: GLUE) insider files Form 144 to sell 11,845 shares on 06/23/2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPS1RuSlZnMmpZa21XcC1OdTRmN3hvY3Q4c2tMY0s0TmdlazFTVjRwdTN3NTRqZ0tYM0lwclNiUGRuSnJYbmZvQnA4RDMwdndUMW5jaFNydTJqbl94TENwSkRvOHdMUDlpT3JmZmxDa0tHOFd3NU5jb2pWN05sdGlCUzJnQ0dLZ3drYlh2dlZyZXNXWHdpa0pGWmlRejlKaTh1X0dBYXNwdw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa (NASDAQ: GLUE) CSO sells 3,000 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOVWh4cTFpenFWMHRhYWhObE5Hei1xX3BadnhpNUVSTDk1RVlTeUk2RmlWb1pOUU9vdktzbXh4MUxjTU5iS3R3WjJyUl9HSU4zTWtsNUtJSkNvSkVIRXNGWm5jWE5aa1hKSm93Ykg4MHhFNGUwRGE1RV9OcDE1LUFCcUpyZG5GN1Zlb3J4Ti1nQ0kzbktvSUFNNFdNZnZ1MXNEcnlnY3hBVHQ3aHJFcGRPUUs1czZXQVhDb0dHLVhB?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Monte Rosa (GLUE) awarded 25,800 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOQWVDNnhidXdaWW5xZDN0TEgxM0xYc2FCY2VJSGRqMnpaUEZ1cjVkdlBhUDBWVDd2VkFScTNYTUZJY1NlZnYyNFYtaEhIczJVY0xyVUZqVGxiOEZKUzlnSnd6alhFWmJCWXVZU3J0SzM1Y05uYzNUV0dOMi1ES3dReWZRYnpBZXJXOUNFUERqZ2Y3ZlFrMDFEVEpkYzR5dzZRQ18ta1JuSVVmY08tMVB6Ul9kZTVPSDBvQUk0YW9B?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (GLUE): Best Growth Stocks Under $20 to Buy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monte-rosa-therapeutics-glue-best-180019178.html", "source_name": "Insider Monkey", "published_at": "2026-06-03T18:00:19+00:00", "published_display": "03 Jun 2026 18:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monte-rosa-therapeutics-participate-upcoming-110000322.html", "source_name": "GlobeNewswire", "published_at": "2026-05-20T11:00:00+00:00", "published_display": "20 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Trial Progress And Valuation Gap Draw Investor Attention", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/monte-rosa-trial-progress-valuation-002431921.html", "source_name": "Simply Wall St.", "published_at": "2026-05-10T00:24:31+00:00", "published_display": "10 May 2026 00:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monte-rosa-therapeutics-glue-reports-151505773.html", "source_name": "Zacks", "published_at": "2026-05-07T15:15:05+00:00", "published_display": "07 May 2026 15:15", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monte-rosa-therapeutics-q1-earnings-131804201.html", "source_name": "Associated Press", "published_at": "2026-05-07T13:18:04+00:00", "published_display": "07 May 2026 13:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/monte-rosa-therapeutics-announces-first-110000914.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T11:00:00+00:00", "published_display": "07 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise", "summary": "", "url": "https://finance.yahoo.com/m/23019c27-1112-378b-859e-30d2884f46b1/monte-rosa-ceo-sells-%24141k-in.html", "source_name": "Motley Fool", "published_at": "2026-04-21T17:53:49+00:00", "published_display": "21 Apr 2026 17:53", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What You Need To Know About The Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Analyst Downgrade Today", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics (GLUE) Quarterly Loss Tests Bullish Profitability Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Market Doesn't Like What It Sees From Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) Revenues Yet As Shares Tumble 26%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-14T08:00:00+00:00", "published_display": "14 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_wFBVV95cUxNNERPc0lNSThISlE4cno3c2pOS1M0bGV1VTZnTHI5NHJSVDdZdS1tdk4tZUlyM29xZUtjbmxodGQteVUxaVd2bDZyTzVUR0VKcGRkVGUwVkFoWm9CWlZNR2k4RUlXOHhSSnJMQnNnWGdfbjlHT0pYdTdpUXJ2eEdEdENUMWNMejlTbjBiTXN4SC1wVFlZNnZ4MnJOQ1RmWFFVT2szd1piTXlOTXRRY2dxM0V6TmF0M3FGOC1HTHYwbXBmQVhORktpcUtlRkY0V1p0c2VqYnl0ODl0dDF1ZmVhdTNSVmZSWjNjY0FMTFVEMTFKTldSeEMxZWNJRjhjUkU?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Monte Rosa Therapeutics And The Promise Of Molecular Glue Degraders", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOeHQwWjJKY1I2YWhrY0gwa2kxb01GU1Jvak16ZWV6b0p2ZGp1VFNYTFpfUG5DaTlsU1E1bmJITldzNHBVN1R4d2VnRllNQ0FWWGhHTXZ2MFNoUWRvY29kMzhlSDRwcWNaakhEbTlwMGNlZFhsSV9aYU8yeUxfSXVJV1Z6d3d6bjZuZUxPX1VYVExyc3pzdmYwMmRCTWtETWJsX1l1Rlg3Vy1fcXM4?oc=5", "source_name": "Seeking Alpha", "published_at": "2025-09-16T07:00:00+00:00", "published_display": "16 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 92, "total_relevant": 55, "sentiment_summary": {"positive": 9, "negative": 8, "neutral": 38, "score": 51, "total": 55, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 19.6, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 6.75, "count": 13}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 23.04, "latest_week": "2026-07-10", "one_week_move": -4.8, "four_week_move": 26.4, "twelve_week_move": 16.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.850308, "market_dynamics_buy_signal": false, "relative_strength": 35.74334, "fair_value_gap": 167.6, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.487, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.8% over one week, +26.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 60, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 15}, {"label": "simplywall.st", "count": 6}, {"label": "Market source", "count": 5}, {"label": "MarketBeat", "count": 4}, {"label": "Investing.com Canada", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "Simply Wall Street", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 47}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "47", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-4.8% over one week, +26.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "GLUE (NASDAQ: GLUE) holder plans 4,351-share sale after option exercise"}], "updated_at": "2026-07-16T08:52:16.917818+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}